| MeSH term | MeSH ID | Detail |
|---|---|---|
| Scorpion Stings | D065008 | 1 associated lipids |
| Drug-Related Side Effects and Adverse Reactions | D064420 | 3 associated lipids |
| Retrognathia | D063173 | 1 associated lipids |
| End Stage Liver Disease | D058625 | 1 associated lipids |
| Candidiasis, Invasive | D058365 | 2 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Thrombotic Microangiopathies | D057049 | 1 associated lipids |
| Central Serous Chorioretinopathy | D056833 | 1 associated lipids |
| Leukoencephalopathies | D056784 | 3 associated lipids |
| Netherton Syndrome | D056770 | 1 associated lipids |
| Latent Tuberculosis | D055985 | 1 associated lipids |
| Invasive Pulmonary Aspergillosis | D055744 | 1 associated lipids |
| Keratosis, Actinic | D055623 | 3 associated lipids |
| Multiple Pulmonary Nodules | D055613 | 2 associated lipids |
| Pancreatitis, Graft | D055589 | 1 associated lipids |
| Failed Back Surgery Syndrome | D055111 | 3 associated lipids |
| Primary Graft Dysfunction | D055031 | 1 associated lipids |
| Idiopathic Interstitial Pneumonias | D054988 | 1 associated lipids |
| Dendritic Cell Sarcoma, Interdigitating | D054739 | 1 associated lipids |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | D054198 | 10 associated lipids |
| Posterior Leukoencephalopathy Syndrome | D054038 | 1 associated lipids |
| Dysuria | D053159 | 1 associated lipids |
| Nocturia | D053158 | 1 associated lipids |
| Delayed Graft Function | D051799 | 2 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Lymphohistiocytosis, Hemophagocytic | D051359 | 1 associated lipids |
| Granulomatosis, Orofacial | D051261 | 2 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Dyslipidemias | D050171 | 7 associated lipids |
| Diabetes Complications | D048909 | 4 associated lipids |
| Hepatic Insufficiency | D048550 | 1 associated lipids |
| Colitis, Collagenous | D046729 | 1 associated lipids |
| Protoporphyria, Erythropoietic | D046351 | 1 associated lipids |
| Coproporphyria, Hereditary | D046349 | 1 associated lipids |
| Ileus | D045823 | 3 associated lipids |
| Intestinal Volvulus | D045822 | 1 associated lipids |
| Cholecystolithiasis | D041761 | 2 associated lipids |
| Mastocytosis, Cutaneous | D034701 | 1 associated lipids |
| Hypoalbuminemia | D034141 | 1 associated lipids |
| Hyperuricemia | D033461 | 4 associated lipids |
| Papillomavirus Infections | D030361 | 4 associated lipids |
| Denys-Drash Syndrome | D030321 | 1 associated lipids |
| Pulmonary Disease, Chronic Obstructive | D029424 | 16 associated lipids |
| Polyomavirus Infections | D027601 | 1 associated lipids |
| Coronary Stenosis | D023921 | 6 associated lipids |
| Lacerations | D022125 | 1 associated lipids |
| Brachial Plexus Neuritis | D020968 | 2 associated lipids |
| Neuroaspergillosis | D020953 | 2 associated lipids |
| Hypoxia-Ischemia, Brain | D020925 | 22 associated lipids |
| Central Nervous System Viral Diseases | D020805 | 1 associated lipids |
| Intracranial Thrombosis | D020767 | 2 associated lipids |
| Parkinsonian Disorders | D020734 | 20 associated lipids |
| Nervous System Autoimmune Disease, Experimental | D020721 | 3 associated lipids |
| Stroke | D020521 | 32 associated lipids |
| Brain Infarction | D020520 | 17 associated lipids |
| Peroneal Neuropathies | D020427 | 1 associated lipids |
| Sciatic Neuropathy | D020426 | 13 associated lipids |
| Osteoarthritis, Knee | D020370 | 13 associated lipids |
| Paraneoplastic Syndromes, Nervous System | D020361 | 1 associated lipids |
| Hypertensive Encephalopathy | D020343 | 1 associated lipids |
| Migraine with Aura | D020325 | 1 associated lipids |
| Autoimmune Diseases of the Nervous System | D020274 | 1 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Ventricular Remodeling | D020257 | 28 associated lipids |
| Infarction, Middle Cerebral Artery | D020244 | 35 associated lipids |
| Optic Nerve Injuries | D020221 | 4 associated lipids |
| Facial Nerve Injuries | D020220 | 1 associated lipids |
| Trauma, Nervous System | D020196 | 2 associated lipids |
| Nocturnal Myoclonus Syndrome | D020189 | 1 associated lipids |
| Sleep Apnea, Central | D020182 | 1 associated lipids |
| Citrullinemia | D020159 | 1 associated lipids |
| Hepatopulmonary Syndrome | D020065 | 1 associated lipids |
| Epstein-Barr Virus Infections | D020031 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Miller Fisher Syndrome | D019846 | 1 associated lipids |
| Hepatitis C, Chronic | D019698 | 12 associated lipids |
| Hepatitis B, Chronic | D019694 | 4 associated lipids |
| Hepatitis, Autoimmune | D019693 | 1 associated lipids |
| Neurodegenerative Diseases | D019636 | 32 associated lipids |
| Intracranial Hypertension | D019586 | 4 associated lipids |
| Dermatitis, Perioral | D019557 | 4 associated lipids |
| Pouchitis | D019449 | 3 associated lipids |
| Endotoxemia | D019446 | 27 associated lipids |
| Oral Ulcer | D019226 | 1 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Fasciitis, Necrotizing | D019115 | 1 associated lipids |
| Postoperative Hemorrhage | D019106 | 7 associated lipids |
| Multiple Endocrine Neoplasia Type 2a | D018813 | 1 associated lipids |
| Anemia, Iron-Deficiency | D018798 | 6 associated lipids |
| Encephalitis, Viral | D018792 | 3 associated lipids |
| Hypoplastic Left Heart Syndrome | D018636 | 1 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Lichen Sclerosus et Atrophicus | D018459 | 2 associated lipids |
| Vasculitis, Leukocytoclastic, Cutaneous | D018366 | 5 associated lipids |
| Hutchinson's Melanotic Freckle | D018327 | 2 associated lipids |
| Angiofibroma | D018322 | 2 associated lipids |
| Cervical Intraepithelial Neoplasia | D018290 | 1 associated lipids |
| Seminoma | D018239 | 2 associated lipids |
| Smooth Muscle Tumor | D018235 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Pompeo A et al. | Cyclosporin A, but not FK506, increases arachidonic acid release and inhibits proliferation of pituitary corticotrope tumor cells. | 1999 | Life Sci. | pmid:10096434 |
| Kenyon NS et al. | Islet transplantation: present and future perspectives. | 1998 | Diabetes Metab Rev | pmid:10095999 |
| Nakahama H et al. | Effect of FK 506 in the treatment of autoimmune glomerulonephritis in Brown Norway rats. | 1999 | Nephron | pmid:10095178 |
| Kimura T et al. | N-glycosylation is involved in the sensitivity of Saccharomyces cerevisiae to HM-1 killer toxin secreted from Hansenula mrakii IFO 0895. | 1999 | Appl. Microbiol. Biotechnol. | pmid:10091323 |
| Crabtree GR | Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. | 1999 | Cell | pmid:10089876 |
| Liang J et al. | Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. | 1999 | Acta Crystallogr. D Biol. Crystallogr. | pmid:10089303 |
| Trimbur GM et al. | Cloning, sequencing, and nucleolar targeting of the basal-body-binding nucleolar protein BN46/51. | 1999 | J. Cell. Sci. | pmid:10085251 |
| Yura H et al. | Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. | 1999 | J Control Release | pmid:10084872 |
| Webber SA | 15 years of pediatric heart transplantation at the University of Pittsburgh: lessons learned and future prospects. | 1997 | Pediatr Transplant | pmid:10084782 |
| Atkison P et al. | Small bowel transplantation in children. | 1997 | Pediatr Transplant | pmid:10084770 |
| Shapiro R | Tacrolimus in pediatric renal transplantation: a review. | 1998 | Pediatr Transplant | pmid:10084728 |
| Vieregge B et al. | Synergistic effects of the alkaloid sinomenine in combination with the immunosuppressive drugs tacrolimus and mycophenolic acid. | 1999 | Planta Med. | pmid:10083851 |
| Cirocco RE et al. | Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083604 |
| Fu F et al. | Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083555 |
| Chiba K et al. | FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083549 |
| Hoshino Y et al. | FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083547 |
| Jiang H et al. | Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083538 |
| Schorlemmer HU et al. | Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083529 |
| Wu MS et al. | Cyclosporine, but not FK506 and rapamycin, enhances Na(+)-K(+)-CL- cotransport activity in cultured medullary thick ascending limb cells. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083527 |
| Yamashita K et al. | Effect of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083526 |
| Mohamed MA et al. | The effect of cyclosporin A and tacrolimus on cultured human epithelial cells: the role of TGF-beta. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083523 |
| Zanker B et al. | Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083521 |
| Zuckermann A et al. | Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083518 |
| Kokado Y et al. | Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083515 |
| Opelz G | Immunosuppression with FK 506 does not improve kidney graft survival. Collaborative Transplant Study. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083513 |
| Shapiro R et al. | A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083507 |
| Steinmueller T et al. | The effect of cyclosporine vs FK 506 on glucose metabolism. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083504 |
| Yang HC et al. | Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083501 |
| Klupp J et al. | Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083497 |
| McAlister VC et al. | Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083495 |
| Navia MA | Rational design of new immunosuppressive drugs. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083489 |
| Song Z et al. | FK 506 prevents islet xenograft rejection: a study in the pig-to-rat model. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083437 |
| Terakura M et al. | Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083380 |
| Kaibori M et al. | Inhibition of iNOS induction by FK506, but not by cyclosporine, in rat hepatocytes. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083347 |
| Rao AS et al. | Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083302 |
| Rastellini C et al. | Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083278 |
| Stratta RJ | Optimal immunosuppression in pancreas transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083263 |
| Kaufman DB et al. | Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083261 |
| Humar A et al. | Surgical complications requiring early relaparotomy after pancreas transplantation: comparison of the cyclosporine and FK 506 eras. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083256 |
| Kandaswamy R et al. | Vascular graft thrombosis after pancreas transplantation: comparison of the FK 506 and cyclosporine eras. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083254 |
| Damotte D et al. | Morphologic features of large bowel biopsies in combined small and large bowel transplantations could predict clinical rejection. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083252 |
| Schulz T et al. | Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083251 |
| Murase N et al. | Immunomodulation of intestinal transplant with allograft irradiation and simultaneous donor bone marrow infusion. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083238 |
| Fischer L et al. | Hepatitis G virus infection in liver transplant recipients. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083208 |
| Rayes N et al. | Treatment of hepatitis B-reinfection or de novo-infection after liver transplantation with famciclovir--how effective is it? | 1999 Feb-Mar | Transplant. Proc. | pmid:10083200 |
| Molmenti E et al. | Noncompliance after pediatric liver transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083164 |
| Mueller AR et al. | Is the use of marginal liver grafts justified? | 1999 Feb-Mar | Transplant. Proc. | pmid:10083160 |
| Kato T et al. | Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083158 |
| Lohmann R et al. | Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083151 |
| Tacrolimus in renal transplantation: a comparison of induction vs noninduction therapy (triple therapy): three-month results. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083131 |